Last update: Sept. 28, 2015

C27 H29 N5 O6 S

Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Indicated for the treatment of pulmonary arterial hypertension.

Pharmacokinetic data (moderately high molecular weight and high percentage of protein binding capacity) make it unlikely a milk passage in significant amounts.
Low oral bioavailability hinders its passage from the ingested milk to infant's plasma, except in preterm and immediate neonatal period that may show an increased intestinal permeability.

Although no samples have been taken to analyze the concentration in breast milk, a 30 weeks old premature infant who was breastfed for 2-and-a-half months, while his mother was treated with Bosentan and Sildenafil, did not present side-effects.

It is approved for Pediatric use from 1-year-old or 10 kg to higher, but there are not published data on neonatal indication.

It would be preferred a safer alternative until more data is available about this drug regarding breastfeeding, especially during the neonatal period and in case of prematurity.


We do not have alternatives for C27 H29 N5 O6 S.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C27 H29 N5 O6 S is Bosentan in Molecular formula.

Is written in other languages:


C27 H29 N5 O6 S belongs to this group or family:


Main tradenames from several countries containing C27 H29 N5 O6 S in its composition:


Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 552 daltons
Protein Binding 98 %
VD 0,26 l/Kg
Tmax 3 - 5 hours
T1/2 5 hours


  1. Pediamécum (AEP). Bosentan. Ficha técnica. 2014 Full text (link to original source) Full text (in our servers)
  2. AEMPS. Bosentan. Ficha técnica. 2013 Full text (in our servers)
  3. Nakwan N, Choksuchat D, Saksawad R, Thammachote P, Nakwan N. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr. 2009 Abstract
  4. Goissen C, Ghyselen L, Tourneux P, Krim G, Storme L, Bou P, Maingourd Y. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr. 2008 Abstract
  5. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart. 2006 Abstract
  6. Molelekwa V, Akhter P, McKenna P, Bowen M, Walsh K. Eisenmenger's syndrome in a 27 week pregnancy--management with bosentan and sildenafil. Ir Med J. 2005 Abstract
  7. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Abstract
  8. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004 Abstract
  9. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PL. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by AELAMA

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM